David Johnson Einstein

The paper examines immune infiltration in prostate cancer, finding higher T-cell density correlates with reduced CD8 effector cells and increased TIGIT, suggesting immune suppression.

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

This paper identifies FOXJ1 as a mediator of taxane resistance in prostate cancer by regulating microtubule dynamics, with clinical implications for patient stratification.

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

The paper shows that ctDNA is undetectable in localized prostate cancer but present in metastatic cases, suggesting lower dissemination and detectability in early stages.